A recent survey by KFF found 6% of US adults have a prescription for GLP-1 agonists like Wegovy. About 25,000 start Wegovy weekly, yet experts are concerned about long-term efficacy and side effects.
In the SELECT trial of 17,600 adults, those on semaglutide continuously lost weight over 65 weeks, sustaining it for four years. 17% left due to side effects, including nausea and diarrhea.
[
add
]
[
|
|
...
]